Reduction of the immunosuppressive action of chemotherapeutics in patients with mammary carcinoma by Azimexon.

Abstract

Patients treated by aggressive cytostatic treatment exhibit marked deficiencies in cell-mediated immunity. Our investigations were performed in order to find out whether these immunosuppressive effects could be diminished by supportive treatment with the new synthetic immunomodulating compound BM 12.531, INN: AZIMEXONE. After inducing remission in ten patients with metastasizing breast cancer by a combination chemotherapy given for about one year, leucocytes, T- and B-lymphocytes and reactivity of peripheral lymphocytes to different mitogens were determined at weekly intervals before (8 X), during (8 X while on 100 mg i.v. weekly, then 4 X while on 400 mg i.v. weekly) and after (4 X) treatment with AZIMEXONE. Chemotherapy-induced immunosuppression could be markedly diminished during the administration of AZIMEXONE. A significant increase in the peripheral leucocyte count and mitogen-induced lymphocyte transformation could be achieved without any marked influence on the percentages of T- and B-cells. No severe side-effects of AZIMEXONE were observed.

• Authors: R Kreienberg, D Boerner, F Melchert, E M Lemmel
• Journal: Journal of immunopharmacology (J Immunopharmacol) Vol. 5 Issue 1-2 Pg. 49-64 ( 1983) ISSN: 0163-0571 [Print] United States
• PMID: 6606686 (Publication Type: Journal Article)

Chemical References

• Aziridines
• Azirines
• azimexon

Topics

• Aziridines (adverse effects, therapeutic use)
• Azirines (therapeutic use)
• B-Lymphocytes (immunology)
• Breast Neoplasms (drug therapy)
• Cells, Cultured
• Female
• Humans
• Immunosuppression Therapy
• Leukocyte Count
• Lymphocyte Activation (drug effects)
• T-Lymphocytes (immunology)